Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy

被引:8
|
作者
Hussain, Haroon A. [1 ]
Harvey, Amanda J. [1 ]
机构
[1] Brunel Univ London, Brunel Inst Canc Genet & Pharmacogen, Biosci, Kingston Lane, Uxbridge UB8 3PH, Middx, England
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 5卷 / 03期
关键词
Breast tumour kinase; Protein tyrosine kinase 6; Breast neoplasms; Targeted molecular therapy; Intracellular signaling peptides and proteins; Protein kinase inhibitors;
D O I
10.5306/wjco.v5.i3.299
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There have been significant improvements in the detection and treatment of breast cancer in recent decades. However, there is still a need to develop more effective therapeutic techniques that are patient specific with reduced toxicity leading to further increases in patients' overall survival; the ongoing progress in understanding recurrence, resistant and spread also needs to be maintained. Better understanding of breast cancer pathology, molecular biology and progression as well as identification of some of the underlying factors involved in breast cancer tumourgenesis and metastasis has led to the identification of novel therapeutic targets. Over a number of years interest has risen in breast tumour kinase (Brk) also known as protein tyrosine kinase 6; the research field has grown and Brk has been described as a desirable therapeutic target in relation to tyrosine kinase inhibition as well as disruption of its kinase independent activity. This review will outline the current "state of play" with respect to targeted therapy for breast cancer, as well as discussing Brk's role in the processes underlying tumour development and metastasis and its potential as a therapeutic target in breast cancer. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:299 / 310
页数:12
相关论文
共 50 条
  • [1] Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery
    Barinoff, Jana
    Schmidt, Marcus
    Schneeweiss, Andreas
    Schoenegg, Winfried
    Thill, Marc
    Keitel, Stella
    Lattrich, Claus R.
    Hinke, Axel
    Kutscheidt, Andreas
    Jackisch, Christian
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 116 - 124
  • [2] Breast tumour kinase and its role in mTOR signalling
    Harvey, Amanda
    Foster, Helen
    Thorpe, Maria
    Karteris, Emmanouil
    CANCER RESEARCH, 2018, 78 (04)
  • [3] A review on tyrosine kinase inhibitors for targeted breast cancer therapy
    Sankarapandian, Vidya
    Rajendran, Ramya Lakshmi
    Miruka, Conrad Ondieki
    Sivamani, Poornima
    Maran, Balu Alagar Venmathi
    Krishnamoorthy, Rajapandiyan
    Gangadaran, Prakash
    Ahn, Byeong-Cheol
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263
  • [4] The role of angiogenesis in tumour progression of breast cancer
    Gasparini, MDG
    BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 167 - 173
  • [5] TUMOUR DORMANCY IN BREAST CANCER
    Demicheli, Romano
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3257 - 3257
  • [6] Breast cancer tumour vaccines
    Miles, D
    CANCER TREATMENT REVIEWS, 1997, 23 : 77 - 83
  • [7] The tumour microenvironment in breast cancer
    Werb, Zena
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S24 - S25
  • [8] Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy
    Seynaeve, C
    Verhoog, LC
    van de Bosch, LMC
    van Geel, AN
    Menke-Pluymers, M
    Meijers-Heijboer, EJ
    van den Ouweland, AMW
    Wagner, A
    Creutzberg, CL
    Niermeijer, MF
    Klijn, JGM
    Brekelmans, CTM
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (08) : 1150 - 1158
  • [9] Role of breast tumour kinase in the in vitro differentiation of HaCaT cells
    Wang, TC
    Jee, SH
    Tsai, TF
    Huang, YL
    Tsai, WL
    Chen, RH
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (02) : 282 - 289
  • [10] Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
    Raju, V.
    Yasothamani, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S1272 - S1272